Dyadic
About Dyadic
Investor Information
News and Media
Careers
Technology Platform
Genomic Products & Services
Enzymes
Manufacturing Services






Investor Presentation
January 2012
The Power of Proteins
Read more
Article in Renewable Energy Magazine
August 2011
Green Sugars™, the Next Oil
Read more
Article in Biofuels Journal
June 2011
Bioenzyme For Biofuels
Read more
The World Conference on Industrial Biotechnology and Bioprocessing Conference Presentation
May 11, 2011
Efficient Saccharification of Lignocellulosic Feedstocks Using the C1-Technology Platform
Read more
Advance Biofuels Leadership Conference Presentation
April 20, 2011
Continuing Enzymatic Enhancements
Read more
Biofuels International
March 2011
Easy to Digest Enzymes
Read more
Presentation at World Biofuels Markets 2011
March 24, 2011
The C1 technology platform - Facilitating the economic production of lignocellulose based biofuels and chemicals
Read more
Presentation at World Biofuels Markets 2011
March 23, 2011
Cost efficient production of fuels and chemicals based on lignocellulose
Read more
Presentation at Renewable Fuels Association 16th Annual National Ethanol Conference
February 20-22, 2011
Building Bridges To A More Sustainable Future
Read more
Dyadic International, Inc. Presents at Rodman & Renshaw
September 2010
Read more
EnGen Bio Presents at Rodman & Renshaw
September 2010
Read more
Treasure Coast Business Journal
August 2010
Mark Emalfarb of Dyadic International - R&D Powerhouses Never Gives Up
Read more
The Palm Beach Post Money
December 2009
Best, worst performers of 2009 for Palm Beach County and Treasure Coast
Read more
TCPalm.com
November 2009
Future is sweet for Jupiter CEO
Read more
RENEWABLE ENERGY MAGAZINE
October 2009
INTERVIEW: Mark Emalfarb, CEO of biofuel innovator, Dyadic International
Read more
Florida Trend
September 2009
A Matter of Chemistry
Read more
Interviews of Mark Emalfarb at the Sixth Annual World Congress on Industrial Biotechnology & Bioprocessing
August 2009
View Video
South Florida Business Journal
May 2009
Dyadic CEO Makes A Comeback, Company sues prominent legal and accounting firms
Read more
Ethanol Producer Magazine
January 2007
Enabling the Biorefinery Concept
Read more
Ethanol Producer Magazine
January 2007
The Discoverer's Game
Read more
BusinessWeek
December 2006
Put A Termite In Your Tank
Read more
Nature [registration required]
Vol. 444, 7 December 2006
A Field in Ferment
Read more
Entrepreneur
December 2006
Dyadic Snapshot -- Good Genes
Read more
Chicago Tribune
October 13, 2006
Beyond corn: Ethanol's next generation:
Scientists seek cheap, plentiful energy alternatives

Read more
Ethanol Today
October 2006
Cellulosic Ethanol: Harvesting the Potential
Read more
Distillers Grains Quarterly
Fall 2006
Coproduct Breakdown
Read more
Society for Industrial Microbiology Annual Industrial Microbiology and Biotechnology Meeting
August 1, 2006
Presentation by Richard Burlingame, Ph.D.
Read more

U.S. Department of Agriculture
2006
Ethanol Production from Alkaline Peroxide Pretreated Enzymatically Saccharified Wheat Straw
Read more

BioPharm International
May 1, 2006
Maximizing Protein Expression in Filamentous Fungi
Read more

ETHANOL: DOE lays out research plan for cellulosic fuel production
Read Press Release
Breaking the Biological Barriers to Cellulosic Ethanol: A Joint Research Agenda (Full Report)
For information regarding News and Media please contact investors@dyadic.com


 
Dyadic Announces Receipt of Purported Declaration of Default from Mark A. Emalfarb Trust and Other Events

JUPITER, Fla.

January 08, 2008

Dyadic International, Inc. (AMEX: DIL) announced today that on January 2, 2008, Dyadic International (USA), Inc. ("Dyadic Florida"), a wholly-owned subsidiary of Dyadic International, Inc. (the "Company"), received a purported declaration of default (the "2008 Default Notice") from the Mark A. Emalfarb Trust under agreement dated October 1, 1987 ("Emalfarb Trust") relating to Dyadic Florida's Revolving Note in favor of the Emalfarb Trust dated as of May 29, 2003 with a maturity date of January 1, 2009 (as amended to date, the "Note"). Principal under the Note bears interest at the rate of 8% per annum (14% following a default under the Note); the Note has a principal balance of approximately $2.4 million and is secured by certain of Dyadic Florida’s assets. The Emalfarb Trust has as its trustee and beneficiary Mark A. Emalfarb, a director of the Company and the former Chief Executive Officer and President of the Company. According to a Schedule 13D filing (filed on November 13, 2007) (the "13D Filing"), Mark Emalfarb, through the Emalfarb Trust, owned 5,822,125 shares (or approximately 19.4%) of the Company's outstanding shares of common stock as of November 9, 2007. In addition, according to the 13D filing, the Francisco Trust under agreement dated February 28, 1996, whose beneficiaries are the spouse and descendants of Mark Emalfarb, owned 4,844,578 shares (or approximately 15.9%) of the Company's outstanding shares of common stock as of November 9, 2007.

As previously disclosed in the Company's Current Report on Form 8-K (filed on October 24, 2007) (the "October 24 8-K"), on October 3, 2007, Dyadic Florida received a purported written notice of default (the "2007 Default Notice") from the Emalfarb Trust pursuant to the Note and the Security Agreement dated as of May 29, 2003, as amended by the first amendment thereto dated as of August 19, 2004 (the "Security Agreement"). The 2007 Default Notice alleged that, with reference to certain events identified in the 2007 Default Notice and reported in the Company's Current Reports on Form 8-K filed prior to the date of the 2007 Default Notice (the "Events"), Dyadic Florida may be in default under the Note and Security Agreement. The 2008 Default Notice asserts that the Events (as referred to in the 2007 Default Notice, with no new or different events identified) have continued for more than 90 days and purports to declare Dyadic Florida in Default (as defined in the Note) under the Note and that all amounts evidenced under the Note are immediately due and payable to the Emalfarb Trust. The 2008 Default Notice demands payment of all unpaid principal and accrued interest due on the Note, plus approximately $11,000 in legal fees.

As the Company previously reported in the October 24 8-K (with regard to the 2007 Default Notice) and reaffirms here, the Company does not believe that it is in default under the Note. The Company does not believe that any of the Events constitutes a default under the Note. The Company has made all payments required by the terms of the Note. Although no assurances can be given as to the ultimate outcome of this matter, the Company disagrees with the claims in the 2007 Default Notice and the 2008 Default Notice that a default has occurred under the Note and intends to vigorously contest these claims.

As previously disclosed in the Company's Current Report on Form 8-K (filed on December 28, 2007), the six putative class action lawsuits filed against the Company and certain current and former officers and directors of the Company in the United States District Court for the Southern District of Florida were consolidated, and the Court selected a lead plaintiff who is tasked with litigating the claims against the Company on behalf of all putative class members. On December 28, 2007, the Court ordered that the lead plaintiff must file an amended and consolidated complaint by February 25, 2008, and that the Company must respond to such complaint by March 28, 2008. The Company intends to vigorously contest and defend the allegations under the amended and consolidated putative class action complaint, but no assurance can be given as to the timing, costs to defend or the ultimate outcome of this matter.

On January 8, 2008, the Company filed with the Securities and Exchange Commission a Current Report on Form 8-K, which includes discussion of the above-mentioned items.

About Dyadic
Dyadic International, Inc. is a biotechnology company that uses its patented and proprietary technologies to conduct research and development activities for the discovery, development, and manufacture of products and enabling solutions to the bioenergy, industrial enzyme and pharmaceutical industries.

Cautionary Statement for Forward-Looking Statements
Certain statements made in this press release may be considered "forward-looking statements." These forward-looking statements are based upon current expectations and involve a number of assumptions, risks and uncertainties that could cause our actual results, performance or achievements to be materially different from such forward-looking statements. In view of such risks and uncertainties, investors and stockholders should not place undue reliance on our forward-looking statements. Such statements speak only as of the date of this release, and we undertake no obligation to update any forward looking statements made herein. For a discussion of assumptions, risks and uncertainties identified by the Company, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2006, and our subsequent filings with the SEC.

Contact:

Berkman Associates
Investor Relations Counsel to Dyadic International, Inc.
Neil Berkman, 1-310-826-5051
info@berkmanassociates.com



Home Contact Site Map Important Legal Notice   Search © Dyadic 2008